NEW YORK (GenomeWeb News) – Citing pricing pressures in the whole-genome sequencing space and Complete Genomics' rising operating expenses, investment bank William Blair today downgraded the Mountain View, Calif.-based firm's stock to Market Perform.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.